You are here: Home: Audio Program Guide: CCU 3 | 2008: CCU 3 | 2008 Audio
 
  Go to interview Steven A Curley, MD
Go to interview with Steven R Alberts, MD
Go to interview with Leonard B Saltz, MD
Go to interview with Rakesh K Jain, PhD
  To listen to individual tracks, click on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
Steven A Curley, MD
Professor of Surgical Oncology
Charles B Barker Chair in Surgery
The University of Texas
MD Anderson Cancer Center
Houston, Texas

  
  Click here to download the entire interview  
Track 1 Paradigm shift in the surgical approach to hepatic metastases from colorectal cancer (CRC)
Track 2 Impact of advances in systemic therapy on the resectability of hepatic metastases from CRC
Track 3 Management of synchronous asymptomatic or symptomatic primaries and resectable hepatic metastases
Track 4 Influence of prior chemotherapy on risk of surgery for hepatic metastases
Track 5 Indications for referral to a tertiary care center for surgical treatment of hepatic metastases
Track 6 Bevacizumab and wound healing
Track 7 Resection of synchronous or metachronous hepatic and extrahepatic metastases
Track 8 Cytoreductive surgery and hyperthermic peritoneal chemotherapy for peritoneal carcinomatosis
Track 9 Limitations and complications of radiofrequency ablation for liver metastases
Track 10 Imaging studies for resectable liver metastases
     
Steven R Alberts, MD
Professor of Oncology
Mayo Clinic College of Medicine
Rochester, Minnesota

  
  Click here to download the entire interview  
Track 1 EORTC-40983: Perioperative chemotherapy with FOLFOX and surgery versus surgery alone for resectable liver metastases
Track 2 Current investigational strategies in systemic therapy for conversion of initially unresectable hepatic metastases
Track 3 Therapeutic algorithm for chemotherapy-naïve patients with metastatic CRC (mCRC)
Track 4 Potential hepatic toxicity associated with oxaliplatin or irinotecan
Track 5 Timing of perioperative chemotherapy with or without bevacizumab relative to hepatic resection
Track 6 Adjuvant systemic therapy after resection of hepatic metastases
Track 7 Potential implications of clinical trial results with combination anti-EGFR/anti-VEGF therapy in mCRC
Track 8 CRYSTAL trial and the role of K-ras status in identifying patients who may benefit from cetuximab
Track 9 Evaluation of chemotherapy with biologic agents in the adjuvant setting: NSABP-C-08 and NCCTG-N0147
Track 10 NSABP-C-08: Preliminary safety data with adjuvant FOLFOX and bevacizumab
Track 11 Potential mechanisms of action of bevacizumab and cetuximab in the adjuvant setting
Track 12 Tolerability of cetuximab-associated skin rash in adjuvant trials
Track 13 Utility of rash severity and K-ras status as predictors of response to anti-EGFR monoclonal antibodies
Track 14 CONcePT results: Combined Oxaliplatin Neurotoxicity Prevention Trial
Track 15 Role of radiofrequency ablation or embolization in the treatment of hepatic metastases
Track 16 Therapeutic approach for patients with synchronous primary CRC and liver metastases
     
Leonard B Saltz, MD
Professor of Medicine
Weill Medical College of Cornell University
Attending Physician
Colorectal Disease Management Team Leader
Memorial Sloan-Kettering Cancer Center
New York, New York
  
  Click here to download the entire interview  
Track 1 Perspective on the tradeoff of cutaneous toxicity and benefit from the addition of cetuximab to first-line FOLFIRI in the CRYSTAL trial
Track 2 CRYSTAL: K-ras status and efficacy of first-line FOLFIRI with or without cetuximab in mCRC
Track 3 Choosing a biologic in combination with first-line chemotherapy
Track 4 Relationship between skin rash and response to cetuximab
Track 5 Prophylaxes for cetuximab-associated skin rash
Track 6 Role of K-ras mutation testing in clinical decision-making for the use of EGFR monoclonal antibodies
Track 7 Cetuximab-associated hypersensitivity reactions
Track 8 CAIRO 2: A Phase III study of CAPOX and bevacizumab with or without cetuximab in mCRC
Track 9 CALGB-C80405: FOLFOX or FOLFIRI with bevacizumab, cetuximab or the combination in previously untreated mCRC
Track 10 Tolerability of cetuximab-associated skin rash in the adjuvant setting
Track 11 Phase III study of CAPOX versus FOLFOX as first-line therapy for mCRC
Audio
Track 12 Response benefit from the addition of bevacizumab to first-line oxaliplatin-containing chemotherapy
for mCRC
Audio
Track 13 Viewpoint on the current status of “targeted” cancer therapies
Audio
     
Rakesh K Jain, PhD
Andrew Werk Cook
Professor of Tumor Biology
Harvard Medical School
Director, Edwin L Steele
Laboratory for Tumor Biology
Department of Radiation Oncology
Massachusetts General Hospital
Boston, Massachusetts
  
  Click here to download the entire interview  
Track 1 Early investigations of tumor vasculature and chemotherapy delivery
Track 2 Improvement of drug delivery by normalization of the tumor-vascular environment
Track 3 Anti-angiogenic effects of common cancer therapies
Track 4 Bevacizumab alone or in combination with chemoradiation therapy in rectal cancer: Antivascular effects and tumor response
Track 5 Correlation of biomarkers with the effect of chemoradiation therapy/bevacizumab in rectal cancer
Track 6 Circulating endothelial and progenitor cells and response to anti-angiogenic agents
Track 7 Rationale for studies of radiation therapy with bevacizumab
Track 8 Tumor normalization and edema reduction with cediranib in the treatment of glioblastoma multiform
Track 9 Effect of anti-VEGF agents on endothelial and tumor cells
Track 10 Effect of bevacizumab on ascites and edema via reduced vascular permeability
audio
Track 11 Unelucidated long-term risks of adjuvant bevacizumab
audio
Track 12 Anti-VEGF therapy-associated fatigue
audio
Track 13 In memoriam: Dr Judah Folkman